COGT COGENT BIOSCIENCES
Permanent stock page ↗Health Care · Russell 2000
Next earnings: Mon 9 Nov 2026 · estimated
What 8 analyst firms say about COGENT BIOSCIENCES: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 6 months
Analyst view · last 6M
8 rated views · 9 analyst/firm records · 8 firms
Radar score
- Russell 2000 · Top Picks · 6MGood · #56 in the index85
- Russell 2000 · Safest consensus · 6MBelow the Radar threshold of 8077
Recent analyst activity · last 90 days
Our tracked history has 9 reports on COGT from 8 analyst firms in the last 90 days (15 firms in the past year).
Comparing each firm's latest target with its previous one: 2 raised their price target, 2 left it unchanged and 3 have their first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Piper Sandler raised its target from $52.00 (set 18 Feb 2026) to $55.00 on 17 Aug 2026.
Last 6 months. Latest opinion per identifiable analyst within the last 6 months. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Guggenheim | Michael Schmidt | Buy | 12 Aug 2026 | 52.00 USD |
| H.C. Wainwright | Robert Burns | Buy | 15 Sep 2026 | 55.00 USD |
| Leerink Partners | Andrew Berens | Buy | 12 Aug 2026 | 60.00 USD |
| Needham | Ami Fadia | Hold | 20 Jul 2026 | — |
| Piper Sandler | Allison M Bratzel | Buy | 17 Aug 2026 | 55.00 USD |
| Piper Sandler | Christopher Raymond | Buy | 17 Aug 2026 | 55.00 USD |
| UBS | Michael J Yee | Buy | 11 Aug 2026 | 60.00 USD |
| Wedbush | David Nierengarten | Buy | 16 Sep 2026 | 55.00 USD |
| Weiss Ratings | Unnamed analyst | — | 2 Oct 2026 | — |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:38 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.